CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Control (albumin 5%)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)


Name (Synonyms) Correlation
drug169 Berzosertib Wiki 1.00
drug288 Carboplatin Wiki 1.00
drug435 Docetaxel Wiki 1.00
drug733 Laboratory Biomarker Analysis Wiki 1.00
drug361 Convalescent Plasma (anti-SARS-CoV-2 plasma) Wiki 0.71

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D011471 Prostatic Neoplasms NIH 1.00
D002277 Carcinoma NIH 0.71

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0012125 Prostate cancer HPO 1.00
HP:0030731 Carcinoma HPO 0.71

There is one clinical trial.

Clinical Trials


1 A Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti- SARS-CoV-2 Plasma in Close Contacts of COVID-19 Cases

This is a double-blinded, randomized control trial to assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in two groups, RT PCR-positive and asymptomatic or mildly symptomatic at baseline (group B) and PCR-negative at baseline (group C). Both groups will be randomized 1:1 to receive either convalescent plasma qualitatively positive for SARS-CoV-2 antibody (anti-SARS-CoV-2 plasma) or control (albumin 5%).

NCT04390503 SARS-CoV 2 COVID-19 Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma) Biological: Control (albumin 5%)

Primary Outcomes

Description: The efficacy of treatment will be determined by rating disease severity on Day 28, or last rating evaluated, using a seven-category severity scale.

Measure: Rate of Severe Disease

Time: Up to 28 days

Secondary Outcomes

Description: To compare the rate of measurable anti-SARS-CoV-2 titers between recipients of CP (anti-SARS-CoV-2 plasma) versus control (albumin 5%).

Measure: Rate of measurable anti-SARS-CoV-2 titers

Time: Up to 90 days

Description: Compare the rates of SARS-CoV-2 PCR positivity (RT PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (albumin 5%).

Measure: Rate of SARS-CoV-2 PCR Positivity

Time: Up to 28 days

Description: Compare the duration of SARS-CoV-2 PCR positivity (RT PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (albumin 5%).

Measure: Duration of SARS-CoV-2 PCR Positivity

Time: Up to 28 days

Description: Compare the levels of SARS-CoV-2 RNA between the recipients of antiSARS-CoV-2 plasma and control (albumin 5%)

Measure: Levels of SARS-CoV-2 RNA

Time: Up to 28 days


No related HPO nodes (Using clinical trials)